MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1

被引:36
作者
Zhang, Guochao [1 ]
Zhong, Lele [1 ]
Luo, Hao [1 ]
Wang, Shibing [1 ]
机构
[1] Jining Med Univ, Affiliated Jining 1 Peoples Hosp, Dept Breast & Thyroid Surg, Jining 272011, Shandong, Peoples R China
关键词
miR-155-3p; CADM1; breast cancer; MIR-155; EXPRESSION; TSLC1; LUNG; STATISTICS; SUBTYPES; SYSTEM; TARGET; BRAIN; GENE;
D O I
10.2147/OTT.S206180
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background/purpose: Cell adhesion molecule 1 (CADM1) functions as a tumor suppressor and has been identified to be frequently inactivated in breast cancer, and closely associated with patients' poor prognosis and advanced TNM stage. However, the mechanisms underlying CADM1 in breast cancer progression remains incompletely clear. miR-155, a predicted modulator of CADM1 was reported to be overexpressed in breast cancer, and its high expression level was closely related to the malignant progression of breast cancer. The present study aimed to explore whether miR-155-3p could modulate CADM1 expression and then involved in the progression of breast cancer. Methods: The expression patterns of miR-155-3p in breast cancer tissues and cell lines were determined by RT-PCR technology. The relationship between CADM1 and miR-155-3p were determined by the luciferase gene reporter and Western Blot (WB) assays. Cell proliferation, apoptosis rates and tumorigenesis were determined by CCK-8, flow cytometry and in vivo xenotransplanation experiments, respectively. Results: miR-155-3p was up-regulated in breast cancer tissues and cells when compared to the adjacent normal tissues and normal breast MCF 10A cells. The mRNA and protein levels of CADM1 showed opposite expression patterns to that of miR-155-3p expression detected, and miR-155-3p could negatively regulate CADM1 expression in breast cancer MCF-7 cells. Moreover, gain-of function assay showed that overexpression of miR-155-3p promoted cell proliferation, tumorigenesis and repressed cell apoptosis, but these effects were all significantly impaired when the cells were simultaneously transfected with OE-CADM1, the overexpressing vector of CADM1. Conclusion: This study revealed that miR-155-3p could accelerate the progression of breast cancer via down-regulation of CADM1 expression.
引用
收藏
页码:7993 / 8002
页数:10
相关论文
共 29 条
[1]   Breast cancer subtypes and outcomes of central nervous system metastases [J].
Arslan, Ulku Y. ;
Oksuzoglu, Berna ;
Aksoy, Sercan ;
Harputluoglu, Hakan ;
Turker, Ibrahim ;
Ozisik, Yavuz ;
Dizdar, Omer ;
Altundag, Kadri ;
Alkis, Necati ;
Zengin, Nurullah .
BREAST, 2011, 20 (06) :562-567
[2]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[3]   Increased expression of miR-155 and miR-222 is associated with lymph node positive status [J].
Chernyy, Vladimir ;
Pustylnyak, Vladimir ;
Kozlov, Vadim ;
Gulyaeva, Lyudmila .
JOURNAL OF CANCER, 2018, 9 (01) :135-140
[4]   Causes and consequences of microRNA dysregulation in cancer [J].
Croce, Carlo M. .
NATURE REVIEWS GENETICS, 2009, 10 (10) :704-714
[5]   Most mammalian mRNAs are conserved targets of microRNAs [J].
Friedman, Robin C. ;
Farh, Kyle Kai-How ;
Burge, Christopher B. ;
Bartel, David P. .
GENOME RESEARCH, 2009, 19 (01) :92-105
[6]   Loss of TSLC1 expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance [J].
Goto, A ;
Niki, T ;
Li, CP ;
Matsubara, D ;
Murakami, Y ;
Funata, N ;
Fukayama, M .
CANCER SCIENCE, 2005, 96 (08) :480-486
[7]   Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse [J].
Harrell, J. Chuck ;
Prat, Aleix ;
Parker, Joel S. ;
Fan, Cheng ;
He, Xiaping ;
Carey, Lisa ;
Anders, Carey ;
Ewend, Matthew ;
Perou, Charles M. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) :523-535
[8]  
Ishimura M., 2012, J CANC THERAPY, V3, P379, DOI [10.4236/jct.2012.324050, DOI 10.4236/JCT.2012.324050]
[9]   Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial [J].
Krop, Ian E. ;
Kim, Sung-Bae ;
Gonzalez-Martin, Antonio ;
LoRusso, Patricia M. ;
Ferrero, Jean-Marc ;
Smitt, Melanie ;
Yu, Ron ;
Leung, Abraham C. F. ;
Wildiers, Hans .
LANCET ONCOLOGY, 2014, 15 (07) :689-699
[10]   TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer [J].
Kuramochi, M ;
Fukuhara, H ;
Nobukuni, T ;
Kanbe, T ;
Maruyama, T ;
Ghosh, HP ;
Pletcher, M ;
Isomura, M ;
Onizuka, M ;
Kitamura, T ;
Sekiya, T ;
Reeves, RH ;
Murakami, Y .
NATURE GENETICS, 2001, 27 (04) :427-430